HIGH VERSUS STANDARD DOSES OF CORTICOSTEROIDS IN COVID-19 PATIENTS WITH AN ACUTE RESPIRATORY DISTRESS SYNDROME: a controlled observational comparative study.
Monreal, E.; Sainz de la Maza, S.; Natera-Villalba, E.; Beltran-Corbellini, A.; Rodriguez-Jorge, F.; Fernandez-Velasco, J. I.; Walo-Delgado, P.; Muriel, A.; Zamora, J.; Alonso-Canovas, A.; Fortun, J.; Manzano, L.; Montero-Errasquin, B.; Costa-Frossard, L.; Masjuan, J.; Villar, L. M.
Show abstract
INTRODUCTIONDespite the increasing evidence of the benefit of corticosteroids for the treatment of moderate-severe Coronavirus disease 2019 (COVID-19) patients, no data are available about the potential role of high doses of steroids for these patients. METHODSAll consecutive confirmed COVID-19 patients admitted to a single center were selected, including those treated with steroids and an acute respiratory distress syndrome (ARDS). Patients were allocated to the high doses (HD, [≥]250mg/day of methylprednisolone) of corticosteroids or the standard doses (SD, [≤]1.5mg/kg/day of methylprednisolone) at discretion of treating physician. The primary endpoint was the mortality between both cohorts and secondary endpoints were the risk of need for mechanical ventilation (MV) or death and the risk of developing a severe ARDS. RESULTS573 patients were included: 428 (74.7%) men, with a median (IQR) age of 64 (54-73) years. In HD cohort, a worse baseline respiratory situation was observed and male sex, older age and comorbidities were significantly more common. After adjusting by baseline characteristics, HD were associated with a higher mortality than SD (adjusted-OR 2.46, 95% CI 1.58 - 3.83, p<0.001) and with an increased risk of needing MV or death (adjusted-OR 2.50, p=0.001). Conversely, the risk of developing a severe ARDS was similar between groups. Interaction analysis showed that HD increased mortality exclusively in elderly patients. CONCLUSIONOur real-world experience advises against exceeding 1-1.5mg/kg/day of corticosteroids for severe COVID-19 with an ARDS, especially in older subjects. This reinforces the rationale of modulating rather than suppressing immune responses in these patients. SUMMARYIn patients with severe COVID-19, high doses of corticosteroids are associated with a higher mortality and risk of need for mechanical ventilation or death compared to standard doses. This deleterious effect is mainly observed in the elderly.
Matching journals
The top 11 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Acute respiratory distress syndrome after SARS-CoV-2 infection on young adult population: international observational federated study based on electronic health records through the 4CE consortium 92%
- Hydroxychloroquine For The Treatment Of Severe Respiratory Infection By COVID-19: A Randomized Controlled Trial 92%
- Factors Associated with Disease Severity and Mortality among Patients with Coronavirus Disease 2019: A Systematic Review and Meta-Analysis 91%
Similar papers in this journal
- Biometric covariates and outcome in COVID-19 patients: Are we looking close enough? 91%
- Ruxolitinib versus Dexamethasone in Hospitalized Adults with Covid-19: multicenter matched-controlled study 91%
- Increase in diagnoses associated with Post Acute Sequelae of COVID-19 (PASC) before and during the COVID-19 pandemic: a case-control study in the total population of Region Stockholm. 89%
Similar papers in this journal
- Efficacy of remdesivir-containing therapy in hospitalized COVID-19 patients: a prospective clinical experience 93%
- Administration of tocilizumab to patients with high concentrations of IL-6 in the course of COVID-19 is associated with a better prognosis 93%
- Early Outpatient Treatment Of COVID-19: A Retrospective Analysis Of 392 Cases In Italy 92%
Similar papers in this journal
- Early initiation of corticosteroids in patients hospitalized with COVID-19 not requiring intensive respiratory support: cohort study 90%
- Inhaled Corticosteroids for Outpatients with Covid-19: A Meta-Analysis 90%
- Inhaled corticosteroids downregulate SARS-CoV-2-related gene expression in COPD: results from a RCT 89%
Similar papers in this journal
- Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: a single-center retrospective study. 91%
- A shorter symptom-onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis 90%
- Survival analysis of all critically ill patients with COVID-19 admitted to the main hospital in Mogadishu, Somalia, 30 March–12 June 2020: what interventions are proving effective? 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.